Literature DB >> 19965603

Urinary metabolomics in Fxr-null mice reveals activated adaptive metabolic pathways upon bile acid challenge.

Joo-Youn Cho1, Tsutomu Matsubara, Dong Wook Kang, Sung-Hoon Ahn, Kristopher W Krausz, Jeffrey R Idle, Hans Luecke, Frank J Gonzalez.   

Abstract

Farnesoid X receptor (FXR) is a nuclear receptor that regulates genes involved in synthesis, metabolism, and transport of bile acids and thus plays a major role in maintaining bile acid homeostasis. In this study, metabolomic responses were investigated in urine of wild-type and Fxr-null mice fed cholic acid, an FXR ligand, using ultra-performance liquid chromatography (UPLC) coupled with electrospray time-of-flight mass spectrometry (TOFMS). Multivariate data analysis between wild-type and Fxr-null mice on a cholic acid diet revealed that the most increased ions were metabolites of p-cresol (4-methylphenol), corticosterone, and cholic acid in Fxr-null mice. The structural identities of the above metabolites were confirmed by chemical synthesis and by comparing retention time (RT) and/or tandem mass fragmentation patterns of the urinary metabolites with the authentic standards. Tauro-3alpha,6,7alpha,12alpha-tetrol (3alpha,6,7alpha,12alpha-tetrahydroxy-5beta-cholestan-26-oyltaurine), one of the most increased metabolites in Fxr-null mice on a CA diet, is a marker for efficient hydroxylation of toxic bile acids possibly through induction of Cyp3a11. A cholestatic model induced by lithocholic acid revealed that enhanced expression of Cyp3a11 is the major defense mechanism to detoxify cholestatic bile acids in Fxr-null mice. These results will be useful for identification of biomarkers for cholestasis and for determination of adaptive molecular mechanisms in cholestasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965603      PMCID: PMC2853433          DOI: 10.1194/jlr.M002923

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  34 in total

1.  Fxr(-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids.

Authors:  Hanns-Ulrich Marschall; Martin Wagner; Karl Bodin; Gernot Zollner; Peter Fickert; Judith Gumhold; Dagmar Silbert; Andrea Fuchsbichler; Jan Sjövall; Michael Trauner
Journal:  J Lipid Res       Date:  2005-12-04       Impact factor: 5.922

2.  Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice.

Authors:  Peter Fickert; Andrea Fuchsbichler; Hanns-Ulrich Marschall; Martin Wagner; Gernot Zollner; Robert Krause; Kurt Zatloukal; Hartmut Jaeschke; Helmut Denk; Michael Trauner
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 3.  Bile salt biotransformations by human intestinal bacteria.

Authors:  Jason M Ridlon; Dae-Joong Kang; Phillip B Hylemon
Journal:  J Lipid Res       Date:  2005-11-18       Impact factor: 5.922

4.  Potential bile acid metabolites. 16. Synthesis of stereoisomeric 3 alpha,6,7,12 alpha-tetrahydroxy-5 beta-cholanoic acids.

Authors:  T Iida; I Komatsubara; S Yoda; J Goto; T Nambara; F C Chang
Journal:  Steroids       Date:  1990-12       Impact factor: 2.668

5.  Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids.

Authors:  Gernot Zollner; Martin Wagner; Tarek Moustafa; Peter Fickert; Dagmar Silbert; Judith Gumhold; Andrea Fuchsbichler; Emina Halilbasic; Helmut Denk; Hanns-Ulrich Marschall; Michael Trauner
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-12-15       Impact factor: 4.052

Review 6.  Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations.

Authors:  Gernot Zollner; Hanns-Ulrich Marschall; Martin Wagner; Michael Trauner
Journal:  Mol Pharm       Date:  2006 May-Jun       Impact factor: 4.939

Review 7.  Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity.

Authors:  Alan F Hofmann
Journal:  Drug Metab Rev       Date:  2004-10       Impact factor: 4.518

8.  Cloning and regulation of cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis.

Authors:  D F Jelinek; S Andersson; C A Slaughter; D W Russell
Journal:  J Biol Chem       Date:  1990-05-15       Impact factor: 5.157

Review 9.  LC-MS-based metabolomics in drug metabolism.

Authors:  Chi Chen; Frank J Gonzalez; Jeffrey R Idle
Journal:  Drug Metab Rev       Date:  2007       Impact factor: 4.518

10.  Metabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation.

Authors:  Yueying Zhen; Kristopher W Krausz; Chi Chen; Jeffrey R Idle; Frank J Gonzalez
Journal:  Mol Endocrinol       Date:  2007-06-05
View more
  13 in total

1.  Metabolomics reveals an essential role for peroxisome proliferator-activated receptor α in bile acid homeostasis.

Authors:  Fei Li; Andrew D Patterson; Kristopher W Krausz; Naoki Tanaka; Frank J Gonzalez
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Hepatobiliary disposition of 3alpha,6alpha,7alpha,12alpha-tetrahydroxy-cholanoyl taurine: a substrate for multiple canalicular transporters.

Authors:  Vandana Megaraj; Takashi Iida; Paiboon Jungsuwadee; Alan F Hofmann; Mary Vore
Journal:  Drug Metab Dispos       Date:  2010-07-19       Impact factor: 3.922

3.  Delineation of biochemical, molecular, and physiological changes accompanying bile acid pool size restoration in Cyp7a1(-/-) mice fed low levels of cholic acid.

Authors:  Ryan D Jones; Joyce J Repa; David W Russell; John M Dietschy; Stephen D Turley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-05-24       Impact factor: 4.052

4.  Lithocholic acid disrupts phospholipid and sphingolipid homeostasis leading to cholestasis in mice.

Authors:  Tsutomu Matsubara; Naoki Tanaka; Andrew D Patterson; Joo-Youn Cho; Kristopher W Krausz; Frank J Gonzalez
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

Review 5.  Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  Metabolites       Date:  2020-01-28

Review 6.  FXR signaling in the enterohepatic system.

Authors:  Tsutomu Matsubara; Fei Li; Frank J Gonzalez
Journal:  Mol Cell Endocrinol       Date:  2012-05-17       Impact factor: 4.102

7.  Abcb11 deficiency induces cholestasis coupled to impaired β-fatty acid oxidation in mice.

Authors:  Yuanyuan Zhang; Fei Li; Andrew D Patterson; Yao Wang; Kristopher W Krausz; Geoffrey Neale; Sarah Thomas; Deepa Nachagari; Peter Vogel; Mary Vore; Frank J Gonzalez; John D Schuetz
Journal:  J Biol Chem       Date:  2012-05-22       Impact factor: 5.157

Review 8.  UPLC-MS for metabolomics: a giant step forward in support of pharmaceutical research.

Authors:  Ala F Nassar; Terence Wu; Samuel F Nassar; Adam V Wisnewski
Journal:  Drug Discov Today       Date:  2016-12-02       Impact factor: 7.851

9.  TGF-β-SMAD3 signaling mediates hepatic bile acid and phospholipid metabolism following lithocholic acid-induced liver injury.

Authors:  Tsutomu Matsubara; Naoki Tanaka; Misako Sato; Dong Wook Kang; Kristopher W Krausz; Kathleen C Flanders; Kazuo Ikeda; Hans Luecke; Lalage M Wakefield; Frank J Gonzalez
Journal:  J Lipid Res       Date:  2012-10-03       Impact factor: 5.922

Review 10.  The metabolomic window into hepatobiliary disease.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  J Hepatol       Date:  2013-05-25       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.